Su frmula molecular es C14H22N4O9 y su masa terica es 390.35 Da
Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial
Researchers have found that only around 40% of people are able to produce urolithin A due to differences in individual gut microbiomes.6 Fortunately, other studies have found that the remaining 60% of people can overcome that limitation through supplementation.12 Most of the potential benefits of urolithin A are attributed to the compounds effects on mitophagy.7 This is when your body cleans up damaged or excess mitochondria,8 then replaces them with new, healthy ones to maintain mitochondrial homeostasis.14 As you age, the rate and effectiveness of the mitophagy process decrease
Most patients receive their injections in our office, where we can ensure proper technique and monitor for any reactions
Practical Tips for Safe Use To get the most out of this combination while keeping risks low, follow these clinical best practices
